微球经肝动脉化疗栓塞术联合放疗治疗不可切除肝癌的有效性和安全性分析

马洺远; 林纲毅; 蔡宗洋; 罗何三; 吴盛喜

doi:10.3969/j.issn.1001-5256.2019.11.020

微球经肝动脉化疗栓塞术联合放疗治疗不可切除肝癌的有效性和安全性分析

DOI: 10.3969/j.issn.1001-5256.2019.11.020

1. 汕头市中心医院血管介入科
2. 汕头市中心医院肿瘤放疗科

基金项目:

2017年汕头市科技计划项目(201711911)；

详细信息

中图分类号: R735.7
计量
- 文章访问数: 1544
- HTML全文浏览量: 80
- PDF下载量: 319
- 被引次数: 0
出版历程
- 收稿日期: 2019-06-19
- 出版日期: 2019-11-20

Efficacy and safety of microsphere transarterid chemoembolization combined with radiotherapy versus microsphere transarterial chemoembolization alone in treatment of patients with unresectable liver cancer

Department of Vascular Interventional Radiology,Shantou Central Hospital

Research funding:

摘要

摘要: 目的探讨微球经肝动脉化疗栓塞术（TACE）联合放疗治疗不可切除肝癌的有效性和安全性。方法选取2016年1月-2018年10月在汕头市中心医院接受治疗的原发性肝癌患者68例,随机分为微球TACE组（n=34）,微球TACE联合放疗组（n=34）,比较两组患者近期有效率和无进展生存率、总生存率的差异,同时比较两组患者的不良反应,评估治疗的安全性。计数资料组间比较采用χ2检验,两组患者无进展生存率和总生存率的比较采用Kaplan-Meier法和Log-Rank检验。结果截止至末次随访2019年4月30日,所有患者均完成计划治疗,中位随访15. 2个月,死亡25例。微球TACE组客观缓解率为50. 0%,微球TACE联合放疗组客观缓解率为76. 5%,微球TACE联合放疗组的近期疗效优于微球TACE组（χ2=7. 995,P=0. 046）。微球TACE组6、12、18和24个月的总生存率和无进展生存率分别为94. 1%和76. 5%,69. 0%和47. 1%,51. 3%和23. 9%,30. 9%和9. 6%,微球TACE联合放疗组6、12、1...
- 肝肿瘤 /
- 化学栓塞,治疗性 /
- 放射疗法
Abstract: Objective To investigate the efficacy and safety of microsphere transarterial chemoembolization( TACE) combined with radiotherapy in the treatment of patients with unresectable liver cancer. Methods A total of 68 patients with unresectable liver cancer were enrolled in Shantou central hospital from January 2016 to October 2018,among whom there were 65 male and 3 female patients,with a median age of 55 years( range 36-75 years). These patients were randomly divided into microsphere TACE group with 34 patients and microsphere TACE combined with radiotherapy group( combined group with 34 patients). The two groups were compared in terms of short-term response rate,progression-free survival( PFS) rate,overall survival( OS) rate,and adverse events to evaluate safety. The chi-square test was used for comparison of categorical data between groups,and the Kaplan-Meier method and the log-rank test were used for comparison of PFS and OS rates. Results Up to the last follow-up on April 30,2019,all patients completed treatment as planned and the median follow-up time was 15. 2 months. A total of 25 deaths were observed. The objective response rate was 50. 0% in the microsphere TACE group and 76. 5% in the combined group,and the combined group had a significantly better short-term response than the microsphere TACE group( χ2= 7. 995,P = 0. 046). For the microsphere TACE group,the 6-,12-,18-,and 24-month OS and PFS rates were 94. 1%/76. 5%,69. 0%/47. 1%,51. 3%/23. 9%,and 30. 9%/9. 6%,respectively,and for the combined group,the 6-,12-,18-,and 24-month OS and PFS rates were 100%/93. 7%,87. 8%/81. 1%,75. 1%/52. 9%,and 58. 2%/44. 1%,respectively; the combined group had significantly better PFS and OS time than the microsphere TACE group( χ2= 9. 027 and 4. 288,P = 0. 002 7 and 0. 038). There was a low incidence rate of adverse events in the two groups,and no treatment-related death was observed. Conclusion Compared with microsphere TACE alone,microsphere TACE combined with radiotherapy significantly improves short-term response and long-term survival in patients with unresectable liver cancer and thus provides a more effective and safer treatment for such patients.
- liver neoplasms /
- chemoembolization,therapeutic /
- radiotherapy

HTML全文

参考文献(23)

[1] TORRE LA,BRAY F,SIEGEL RL,et al. Global cancer statistics,2012[J]. CA Cancer J Clin,2015,65(2):87-108.

[2] Chinese Expert Consensus Statement Chinese Society of Liver Cancer(CSLC), Chinese Society of Clinical Oncology(CSCO),Liver Cancer Group,Chinese Society of Hepatology.Consensus on standardized diagnosis and treatment of primary liver cancer[J]. J Clin Hepatol,2009,25(2):83-92.(in Chinese)中国抗癌协会肝癌专业委员会，中国抗癌协会临床肿瘤学协作专业委员会，中华医学会肝病学分会肝癌学组．原发性肝癌规范化诊治的专家共识[J]．临床肝胆病杂志，2009,25(2):83-92.

[3] BETTINGER D,GKIKA E,SCHULTHEISS M,et al. Comparison of local tumor control in patients with HCC treated with SBRT or TACE:A propensity score analysis[J]. BMC Cancer,2018,18(1):807.

[4] WANG H,PAN YG,XIA JT,et al. Clinical effect of transcatheter arterial chemoembolization in treatment of primary liver cancer:Application and research advances[J]. J Clin Hepatol,2018,34(2):414-418.(in Chinese)王辉，潘裕国，夏金堂，等．经肝动脉化疗栓塞术在原发性肝癌治疗中的应用[J]．临床肝胆病杂志，2018,34(2):414-418.

[5] CHIANG CL,CHAN MKH,YEUNG CSY,et al. Combined stereotactic body radiotherapy and trans-arterial chemoembolization as initial treatment in BCLC stage B-C hepatocellular carcinoma[J]. Strahlenther Onkol,2019,195(3):254-264.

[6] WANG HY. Clinical effect of Embosphere microsphere in transarterial chemoembolization for liver cancer[D]. Qingdao:Qingdao University,2017.(in Chinese)王洪雨．Embosphere微球在肝癌TACE治疗中的临床疗效分析[D]．青岛:青岛大学，2017.

[7] WU BL,ZHOU J,LING GH,et al. Efficacy and safety analysis of 8Spheres microspheres combined with lipiodol TACE in the treatment of hepatocellular carcinoma[J]. Med J Wuhan Univ,2018,39(2):248-252.(in Chinese)吴宝林，周军，凌公豪，等．8Spheres微球联合碘油TACE治疗原发性肝癌的疗效及安全性[J]．武汉大学学报:医学版，2018,39(2):248-252.

[8] National Health and Family Planning Commission of the People's Republic of China. Diagnosis,management,and treatment of hepatocellular carcinoma(V2017)[J]. J Clin Hepatol,2017,33(8):1419-1431.(in Chinese)中华人民共和国国家卫生和计划生育委员会．原发性肝癌诊疗规范(2017年版)[J]．临床肝胆病杂志，2017,33(8):1419-1431.

[9] Chinese College of Interventionalists,Chinese Med. Chinese Clinical Practice Guidelines for transarterial chemoembolization of hepatocellular carcinoma[J]. Chin J Radiol,2019,54(3):246-255.(in Chinese)中国医师协会介入医师分会．中国肝细胞癌经动脉化疗栓塞治疗(TACE)临床实践指南[J]．中华放射学杂志，2019,54(3):246-255.

[10] SEYAL AR,GONZALEZ-GUINDALINI FD,ARSLANOGLU A,et al. Reproducibility of m RECIST in assessing response to transarterial radioembolization therapy in hepatocellular carcinoma[J]. Hepatology,2015,62(4):1111-1121.

[11] CHEN LC,CHIOU WY,LIN HY,et al. Comparing stereotactic ablative radiotherapy(SABR)versus re-trans-catheter arterial chemoembolization(re-TACE)for hepatocellular carcinoma patients who had incomplete response after initial TACE(TASABR):A randomized controlled trial[J]. BMC Cancer,2019,19(1):275.

[12] LIU LB,WANG JF,CHENG GH,et al. Explanation of diagnostic criteria for radiation-induced liver diseases[J]. Int J Radiat Med Nuclear Med,2012,36(4):252-255.(in Chinese)刘丽波，王剑峰，程光惠，等．《放射性肝病诊断标准》解读[J]．国际放射医学核医学杂志，2012,36(4):252-255.

[13] LI SY,WU S,CHEN TS,et al. Effect of portal venous perfusion cinobufacini injection combined with TACE in patients with intermediate hepatocellular carcinoma[J]. Clin J Med Offic,2017,45(9):884-886.(in Chinese)李淑英，吴申，陈挺松，等．经导管肝动脉栓塞化疗联合华蟾素门静脉灌注治疗中期原发性肝癌疗效研究[J]．临床军医杂志，2017,45(9):884-846.

[14] KOTHARY N,WEINTRAUB JL,SUSMAN J,et al. Transarterial chemoembolization for primary hepatocellular carcinoma in patients at high risk[J]. J Vasc Interv Radiol,2007,18(12):1517-1526; quiz 1527.

[15] ZHU LL,CAI CF,MENG Y. Therapeutic efficiency of transcatheter arterial chemoembolization combined with intensity modulated radiation therapy against un-resectable primary hepatocellular carcinoma[J]. Int J Med Radiol,2019,42(2):149-153.(in Chinese)朱六玲，蔡陈枫，孟岩．TACE联合调强放疗对不可切除原发性肝癌的疗效研究[J]．国际医学放射学杂志，2019,42(2):149-153.

[16] MA M,NIU TT,SHAO L,et al. Hepatic transcatheter arterial chemoembolization combined with stereotactic radia-tion therapy of primary liver cancer[J]. Trauma and Crit Medicine,2017,5(1):32-35.(in Chinese)马明，牛婷婷，邵亮，等．肝动脉化疗栓塞术联合立体定向放疗治疗较大原发性肝癌临床研究[J]．创伤与急危重病医学，2017,5(1):32-35.

[17] LENG ZQ,LIANG ZY,SHI S. Clinical effect of interventional treatment,radiotherapy,and multimodality therapy for liver cancer[J]. Chin J Radiat Oncol,2000,9(2):99.(in Chinese)冷祝强，梁赵玉，石珊．肝癌介入治疗放射治疗及综合治疗的疗效分析[J]．中华放射肿瘤学杂志，2000,9(2):99.

[18] SEONG J,PARK HC,HAN KH,et al. Clinical results and prognostic factors in radiotherapy for unresectable hepatocellular carcinoma:A retrospective study of 158 patients[J]. Int J Radiat Oncol Biol Phys,2003,55(2):329-336.

[19] ZHANG YW,ZHANG Y,LING ZH,et al. Clinical effect of threedimensional conformal radiotherapy combined with transarterial chemoembolization versus transarterial chemoembolization alone in treatment of liver cancer:A meta-analysis[J]. J South Med Univ,2009,29(12):2514-2516.(in Chinese)张耀伟，张勇，凌志海，等．三维适形放疗联合TACE与单纯TACE治疗肝癌疗效的meta分析[J]．南方医科大学学报，2009,29(12):2514-2516.

[20] LUO JJ,YAN ZP,WANG JH,et al. HCC embolized by microspheres and iodized oil compared with by iodized oil alone[J]. Chin Comput Med Imag,2008,14(2):154-159.(in Chinese)罗剑钧，颜志平，王建华，等．微球+碘化油联合栓塞与碘化油单独栓塞治疗肝癌的比较研究[J]．中国医学计算机成像杂志，2008,14(2):154-159.

[21] ZHANG JX,LI FZ,CHAI J,et al. Clinical and controlled trial of transcatheter arterial chemoembolization with polyvinyl alcohol particle in patients with advanced hepatocellular carcinoma[J]. J Hepatopancreatobiliary Surg,2014,26(3):195-197,203.(in Chinese)张军喜，李发中，柴健，等．微球加碘化油栓塞治疗肝癌疗效的临床对照研究[J]．肝胆胰外科杂志，2014,26(3):195-197,203.

[22] XU YZ,DING YM,YANG Y. Combining chemoembolization using microspheres with iodized oil in the treatment of hepatocellular carcinoma:A Meta-analysis of randomized controlled trials[J]. Chin J Hepatobiliary Surg,2014,20(1):24-28.(in Chinese)徐彦哲，丁佑铭，杨阳．微球联合碘化油栓塞化疗治疗肝细胞癌的Meta分析[J]．中华肝胆外科杂志，2014,20(1):24-28.

[23] CAO G,WEN F. Comparison of microspheres embolization with lipiodol embolization[J]. Chin J Interv Imaging Ther,2016,13(8):518-519.(in Chinese)曹广，温峰．微球栓塞与碘油栓塞的比较[J]．中国介入影像与治疗学，2016,13(8):518-519.

施引文献

资源附件(0)

访问统计